Cresco Labs (OTCMKTS:CRLBF) Raised to "Strong-Buy" at Roth Capital

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) was upgraded by equities researchers at Roth Capital to a "strong-buy" rating in a report issued on Sunday,Zacks.com reports.

CRLBF has been the topic of a number of other research reports. Needham & Company LLC reissued a "hold" rating on shares of Cresco Labs in a research note on Monday, August 12th. Ventum Cap Mkts raised Cresco Labs to a "strong-buy" rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $2.50.

Cresco Labs Price Performance

Shares of Cresco Labs stock traded down $0.20 during trading on Friday, hitting $1.04. The stock had a trading volume of 2,680,260 shares, compared to its average volume of 748,432. The firm has a market cap of $507.67 million, a price-to-earnings ratio of -5.20 and a beta of 1.88. Cresco Labs has a 12 month low of $1.02 and a 12 month high of $2.65. The business's 50-day moving average is $1.59 and its 200 day moving average is $1.71. The company has a current ratio of 2.00, a quick ratio of 1.30 and a debt-to-equity ratio of 1.76.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.